UroGen Pharma (URGN) Misses Q1 EPS by 10c

UroGen Pharma (NASDAQ: URGN) reported Q1 EPS of ($0.97), $0.10 worse than the analyst estimate of ($0.87). Revenue for the quarter came in at $18.78 million versus the consensus estimate of $21.96 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c